# PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma

> **NCT05714306** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Centre Hospitalier Universitaire Vaudois**

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** PEP-DC1
- **BIOLOGICAL:** OC-DC
- **BIOLOGICAL:** PEP-DC2
- **DRUG:** Low dose cyclophosphamide

## Key facts

- **NCT ID:** NCT05714306
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-01
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714306, "PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05714306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*